ArticleGynecologic oncology research and practice2015
Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.
Article in Gynecologic oncology research and practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Clear Cell Carcinoma of the Left Colon: A Case Report.The American journal of case reports · 2026Article
- Segmental specification of the human female fetal reproductive tract revealed by spatiotemporal dynamics.Nature cell biology · 2026Article
- Vascular endothelial generating factor pathway in ovarian cancer.Journal of ovarian research · 2025Review
- Coexistence of giant serous cystadenoma and hemorrhagic corpus luteal cyst in a 12-year-old: diagnostic and fertility-sparing surgical approach.BMC pediatrics · 2025Article
- Long-term survival in a male patient with Müllerian adenocarcinoma of the pelvis: a 15-year case report.Frontiers in oncology · 2025Article
- The neuroepithelial origin of ovarian carcinomas explained through an epithelial-mesenchymal-ectodermal transition enhanced by cisplatin.Scientific reports · 2024Article
- A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination.Gynecologic oncology reports · 2024Article
- Challenges and Considerations in Identifying the Origin of Peritoneal Carcinomatosis: A Case Report.Cureus · 2023Article
- Molecular Histopathology for Establishing Diagnostic Method and Clinical Therapy for Ovarian Carcinoma.Journal of clinical medicine research · 2023Review
- Primary peritoneal high-grade serous carcinoma in a man: A case report.Annals of medicine and surgery (2012) · 2022Article
- Primary peritoneal mucinous cystadenocarcinoma mimicking possible recurrent ovarian mucinous cystadenoma: coincidental pathology or a spectrum of disease?BMJ case reports · 2021Article
- Malignant Müllerian Adenocarcinoma Manifesting With Cardiac Tamponade and Pleural Effusion.Cureus · 2021Article
- Molecular analysis of a rare case of low-grade primary peritoneal serous carcinoma in a male.Rare tumors · 2020Article
- Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.International journal of molecular sciences · 2018Article
- Solitary CNS Metastasis on Initial Presentation of High Grade Serous Carcinoma of the Fallopian Tube.Case reports in obstetrics and gynecology · 2018Article
- Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response.NPJ precision oncology · 2018Article
- The role of immune checkpoint inhibition in the treatment of ovarian cancer.Gynecologic oncology research and practice · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally, epithelial ovarian, tubal, and peritoneal cancers have been viewed as separate entities with disparate origins, pathogenesis, clinical features, and outcomes. Additionally, previous classification systems for ovarian cancer have proposed two primary histologic groups that encompass the standard histologic subtypes. Recent data suggest that these groupings no longer accurately reflect our knowledge surrounding these cancers. In this review, we propose that epithelial ovarian, tubal, and peritoneal carcinomas represent a spectrum of disease that originates in the Mullerian compartment. We will discuss the incidence, classification, origin, molecular determinants, and pathologic analysis of these cancers that support the conclusion they should be collectively referred to as adenocarcinomas of Mullerian origin. As our understanding of the molecular and pathologic profiling of adenocarcinomas of Mullerian origin advances, we anticipate treatment paradigms will shift towards genomic driven therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.